2025 Interim Results Highlights- Total revenue increased by 9.40% YoY to approximately NTD585.31 million- Gross profit increased by 28.98% YoY to approximately NTD201.97 million- Overall gross profit margin rose by 5.24 percentage points to approximately 34.51%- Total comprehensive income attributable to owners of the Company for the period increased significantly by118.02% YoY to approximately NTD68.24 million- Revenue from turnkey solutions reached approximately NTD113.69 million- Basic earnings per share increased by 25.84% YoY to approximately NTD4.87 centsHONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Genes Tech Group Holdings Co. Ltd (“Genes Tech Group” or “The Group”, Stock Code: 8257.HK) announces its interim results for the six months ended 30 June, 2025 (“During the period”). During the period, the Group’s performance demonstrated steady growth. The total revenue of the Group reached approximately NTD585.31 million, representing a year-on- year (“YoY”) increase of 9.40%. Total comprehensive income attributable to owners of the Company for the period amounted to approximately NTD68.24 million, representing a significant YoY increase of 118.02%. Basic earnings per share were approximately NTD4.87 cents, representing a YoY increase of 25.84%.During the period, revenue from turnkey solutions amounted to approximately NTD113.69 million, accounting for approximately 19.42% of the Group’s total revenue. The revenue from trading of parts and used SME amounted to approximately NTD471.62 million, accounting for approximately 80.58% of the Group’s total revenue. The Group adheres to its core strategy of prudence and stability, striving to strengthen the stability and continuity of cooperation with existing international clients while actively expanding new clientele to diversify risks. During the period, the Group’s revenue from operations in the United States increased significantly by 78.54% from last year, accounting for approximately 38.68% of the total revenue of the Group, while revenue from operations in Taiwan increased by 48.97% from last year, accounting for approximately 49.69% of the total revenue the Group.In the first half of 2025, the global semiconductor market continued its growth momentum. Driven by new technologies such as AI, the penetration rates of new technologies and products in areas such as automotive electronics, new energy, the Internet of Things, big data and artificial intelligence continued to rise. Furthermore, the deepening development of cutting-edge technologies such as “AI+” and “5G+”, along with the rapid growth in demand for AI computing power, have become key drivers of semiconductor demand, creating a favorable development environment for semiconductor companies. According to the latest report from the Semiconductor Industry Association (SIA), global semiconductor sales reached USD59 billion in May 2025, up 19.8% from USD49.2 billion in May 2024, marking 19 consecutive months of year-on-year growth and a 3.5% increase from the previous month. The growth in the global chip market was primarily driven by strong demand from the Americas and Asia- Pacific regions.Mr. Yang Ming-Hsiang, Chairman and Chief Executive Officer concluded: “Driven by the strong momentum of AI technology, the semiconductor industry is entering a period of rapid growth in economic profits. However, amidst the current volatile international landscape, the semiconductor industry faces challenges in supply chain stability. The Group will assess the situation, pursue progress while maintaining stability, and continuously enhance its core value and competitiveness to create sustainable long-term investment returns for shareholders.”About Genes Tech Group Holdings Co. Ltd (Stock Code: 8257.HK)Genes Tech Group Holdings Co. Ltd is a turnkey solution provider and exporter of parts and used SME in Taiwan. Since the commencement of its business in 2009, the Group mainly engaged in providing turnkey solution for parts and used SME for its customers and modifying and/or upgrading the semiconductor equipment of its production systems according to customers needs. In addition, the Group is also engaged in the trading of SEM and parts. The SME and parts supplied by the Group included furnaces, clean tracks and other related items, which were used at the front-end of the semiconductor manufacturing process, wafer fabrication such as deposition, photoresist coating and development, and these were extensively applied in mobile phones, game consoles, DVD players, automotive sensors and other digital electronic products.The press release is distributed by Vitalink Consultants Limited on behalf of Genes Tech Group Holdings Co. Ltd. For enquiry, please contact:Ms. Natural Lau  Tel: (852) 2529 7999  Email: Natural.lau@vitalink.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 22, 2025 - (ACN Newswire via SeaPRwire.com) - Everbright Grand China Assets Limited ("Everbright Grand China" or the "Group"; HKEX stock code: 03699.HK), a subsidiary of China Everbright Group, principally engaged in the businesses of property leasing, property management and the sales of properties held for sale, announced its interim results for the six months ended 30 June 2025 ("Reporting Period").During the Reporting Period, revenue of the Group was approximately RMB24.5 million,  representing an increase of approximately RMB0.6 million as compared with 2024. Profit attributable to equity shareholders was approximately RMB10.1 million, representing a decrease of approximately RMB1.3 million as compared with 2024, mainly attributable to the increase in the PRC income tax and deferred taxation. Gross profit was approximately RMB18.1 million, representing an increase of approximately RMB0.6 million as compared with 2024. Basic earnings per share of the Group was approximately RMB2.30 cents (2024: RMB2.59 cents). The Board declared an interim dividend of RMB0.73 cents (equivalent to HK0.80 cents) per ordinary share.Considering that the current operating environment remains relatively challenging, the Board declared an interim dividend of RMB0.73 cents (equivalent to HK0.80 cents) per ordinary share, as a token of appreciation to shareholders for their continuous support. In the second half of the year, the Company will decide on dividend distribution taking into account factors such as business development needs, financial performance and capital position, as well as performance growth, in order to bring the best return to the Company's shareholders and investors.In 2025, global economic environment continues to be characterized by uncertainties. Factors such as geopolitical risks, inflationary pressures and monetary policy adjustments in major economies around the world continue to affect market confidence and capital flows. Nevertheless, the overall stability of China’s economy, the gradual rebound of the consumer market and the continued optimization and upgrading of the industrial structure have provided a solid foundation for the development of the property management and leasing industry.For the six months ended 30 June 2025, the Group generated rental income of approximately RMB17.0 million (2024: RMB16.3 million), representing an increase of approximately RMB0.7 million as compared to the same period last year. The Company’s properties maintained an occupancy rate of approximately 81%, with the overall leasing market performing solidly, although newly signed rents declined compared to the previous period. In the face of downward pressure on rents, the Group will enhance its consolidated earning power by adding additional services to new leases to mitigate the impact of lower rents on overall revenue. This not only enriches the service offerings, but also helps to enhance customer stickiness and satisfaction, further consolidating the Group’s market competitiveness.During the period, revenue from the property management services was approximately RMB7.5 million (2024: RMB7.6 million), representing a decrease of approximately RMB0.1 million as compared to the same period last year. In terms of property portfolio strategy, the Group actively promotes tenant diversification to mitigate industry risks and adapt to the accelerated rise and fall of market environment of various industries. The Group’s existing properties are mainly concentrated in two core cities of Chengdu in Sichuan Province and Kunming in Yunnan Province, covering three commercial buildings, namely Everbright Financial Center, Everbright International Mansion and Ming Chang Building, with a total gross floor area of approximately 89,507 square meters. Benefiting from its excellent geographical location and sound property quality, it has attracted a large number of state-owned enterprises and large organizations to move in and has a solid leasing base. In the future, the Group will promote business diversification to enhance its overall risk-resistant capability.In terms of overseas investment, the Group is evaluating investment opportunities in international markets and is cautiously optimistic about overseas markets. Notwithstanding the volatility of the global economy, the Group will adhere to the principle of prudence and flexibility in its investment horizon to ensure the safety and profitability of its capital operations.As at 30 June 2025, The Group maintained cash and bank balances and bank deposits of approximately RMB236.2 million (31 December 2024: RMB231.5 million). The Group’s gearing ratio, being measured by the Group’s total liabilities over its total assets, was 18.6% (31 December 2024: 18.0%). The Group’s liquidity position was well-managed.Looking ahead to the second half of 2025, there are no new property management projects for the time being, despite favourable lease performance in the first half of the year. The Group is actively looking for suitable investment windows for its acquisition and investment plans which were delayed during the epidemic. With the active domestic economy and falling interest rates, the market’s willingness to invest has increased significantly.The Group will continue to deepen its digital transformation and actively utilize technology to promote the construction of intelligent properties and enhance operational efficiency and customer experience. Through technological empowerment, we optimize the allocation of human resources and service processes, enhance the level of intelligence and refinement of property management, and improve overall service quality and customer satisfaction.In addition, the Group will fully utilize the synergies with its parent company, China Everbright Group, and leverage on the popularity of the “Everbright” brand and its resource advantages to actively develop diversified value-added services, enrich its revenue structure and enhance its brand influence. In the face of industry restructuring and upgrading, the Group insists on stable operation, focuses on risk management and internal control, responds flexibly to changes in the macro-economy and policies, and continues to optimize its asset portfolio in order to enhance its risk-resistant capability. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025. During the reporting period, the Company's business showed strong growth momentum, achieving profitability for the first time. Core product sales and international licensing business progressed in tandem, with multiple ADC pipeline products entering key clinical stages and global commercialization efforts accelerating.Lepu Biopharma is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. Lepu Biopharma is dedicated to developing innovative ADCs through our comprehensive and advanced ADC technology development platform and we aim to develop optimal and innovative drugs to better serve the unmet medical needs of cancer patients. The Company is committed to continuously developing a market-differentiating pipeline by fully integrating independent innovation capabilities and strategic collaborations. The Company has established and is progressively expanding our internal manufacturing capabilities, driven by the business needs stemming from the upcoming commercialization of our ADC candidates.Currently, Lepu Biopharma has strategically designed our pipeline with a range of oncology products. For clinical-stage candidates, the Company has one clinical/commercialization-stage drug candidate; nine clinical-stage drug candidates, including one co-developed through a joint venture; and three clinical-stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the nine clinical-stage drug candidates, seven are targeted therapeutics and two are immunotherapeutics, which are an oncolytic virus drug and T cell agonistic antibody.As of the end of the reporting period, Lepu Biopharma has achieved significant milestones in the monetisation of our R&D capabilities through commercialization and BD activities: PUYOUHENG (Pucotenlimab Injection) has completed the full commercialization process and is currently under a rapid sales growth, and four other products, CMG901, MRG007 and two pre-clinical TCE assets have also been licensed out through our BD activities. Notably, CMG901’s global rights have been licensed to AstraZeneca, and MRG007’s rights for regions outside Greater China have been licensed to ArriVent. Two pre-clinical TCE assets have entered into a collaboration with Excalipoint.Revenue scale achieved a 3.5-fold leapfrog growth, with comprehensive improvement in financial indicatorsIn the first half of 2025, the Company made significant progress in advancing its product pipeline and business operations, recording a total revenue of approximately RMB466 million, which was an increase of 350% of the same period in 2024 at RMB133 million. For licensing activities, the Company has recognized approximately RMB309 million in revenue primarily from the out-licensing of MRG007. The Company recorded a revenue of approximately RMB151 million for the sales of PUYOUHENG (Pucotenlimab Injection), marking a significant increase of 58.8% from the sales recorded in the same period in 2024. In addition, the Group recognized approximately RMB6.3 million in revenue for the provision of CDMO services.During the reporting period, the Company achieved profitability for the first time, with a profit of approximately RMB 29.3 million, marking a turnaround from a loss in the same period of 2024. Net cash generated from operating activities was approximately RMB 46.7 million, and cash and cash equivalents increased to approximately RMB 473 million, representing a positive net operating cash flow compared to the same period in 2024. Research and development expenses amounted to approximately RMB 202 million, representing a decrease of 6.6% compared to the same period in 2024. While ensuring the advancement of core pipelines, cost control measures have shown tangible results.The Company actively develops cooperative relationships with various business channel partners. As of June 30, 2025, the Company completed the tendering process on the procurement platform in 28 provinces of the PRC. We have covered approximately 118 cities in the PRC through various sales channels, and we will further expand our sales network.ADC pipeline enters the critical phase with multiple products, potential for combination therapy highlighted, and fruitful international licensing resultsIn the first half of 2025, the Company remained focused on the research and development of its drug candidates, while continuously assessing market demand and competitive landscape relating to the range of oncology therapeutics and the broad spectrum of indications covered by its drug candidates, in order to maximize the competitiveness of its products pipeline. In particular, MRG003 for NPC nears approval and other key drug candidates advance to pivotal clinical stage.MRG003（EGFR-ADCNPC: MRG003 is under NDA review for the treatment of R/M NPC and has also been granted priority review by the CDE of NMPA. The authority is currently proceeding with the clinical and pharmaceutical evaluation of MRG003. The encouraging data of the pivotal Phase IIb clinical study for the treatment of R/M NPC was read out as “late breaking abstract (LBA)” for oral presentation at the ASCO Congress 2025. The Company is also currently conducting the Phase III clinical trial of combination therapy with MRG003 and pucotenlimab on R/M NPC. The encouraging data in phase II clinical trial of combination therapy on R/M NPC will be presented at the ESMO Congress 2025.HNSCC: As of June 30, 2025, the Company is conducting a randomized, open-label, multicenter Phase III clinical study on HNSCC. In terms of combination therapy with MRG003 and pucotenlimab, we are currently conducting the Phase II clinical trial on HNSCC, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The  European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and the Company will initiate the clinical trial in the second half of 2025.MRG004A (TF-ADC): The Company has completed the Phase I clinical study on solid tumors in China and the encouraging Phase Ib expansion data on PC will be presented at the ESMO Congress 2025. Protocol communication with CDE for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, MRG004A was granted BTD by the CDE in August 2025, which offers a brand-new treatment option to patients with pancreatic cancer.MRG006A (GPC3-ADC): MRG006A is a GPC3-targeted ADC with FIC potential globally. We received IND clearance from the FDA in January 2025. We are currently advancing Phase I clinical trial in China. In pre-clinical studies, MRG006A resulted in a robust and dose-dependent tumor growth inhibition on multiple CDX models and HCC PDX models. In the meantime, MRG006A also demonstrated good tolerability in the exploratory toxicology study.MRG007 (CDH17-ADC): We received the IND approval from the NMPA in June 2025 and are currently conducting a Phase Ia clinical trial for the treatment of unresectable locally advanced or metastatic solid tumors. MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025. In January 2025, the Company entered into an exclusive licensing agreement with ArriVent, pursuant to which the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China. Under the terms of the agreement, the Company is eligible to receive up to US$1.2 billion in total in upfront payment and development, regulatory and sales milestones, together with tiered royalties on net sales. As of June 30, 2025, the upfront payment has been received.CG0070 (Oncolytic virus): CG0070 was granted BTD by the CDE in January 2025. CG0070 is currently in a MRCT Phase III clinical study conducted by the Company’s U.S. partner, CG Oncology. The latest encouraging data observed has been orally presented in the 120th American Urological Association Annual Meeting in April 2025. The Company has completed the Phase I clinical trial in China and are currently engaged in protocol communication with the CDE regarding the domestic bridging pivotal linical trial.Combination therapy layout: As of June 30, 2025, the Company has completed the Phase II trial of combination therapy with MRG002 and pucotenlimab in the treatment of HER2-expressing solid tumors, which has moved to first-line treatment, and protocol communication for phase III clinical trial has been completed. The Company has observed encouraging data on UC. In terms of combination therapy with MRG003 and pucotenlimab, the Company is currently conducting the Phase II clinical trial on HNSCC, which has moved to first-line treatment, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and we will initiate the clinical trial in the second half of 2025, which has been moved up to first-line treatment for advanced disease.Preclinical: Laying the groundwork for innovative platforms and innovative targetsThe Company continuously strives to build up and develop novel technology platforms as innovative engines for the Company. The Company has developed multiple innovative linker-payload platforms for ADC drug candidates, including the Hi-TOPi ADC platform and other early-stage platforms. During the reporting period, our innovative ADC platforms have achieved significant progress. Based on these innovation platforms, the Company has generated two ADC candidates, which are MRG006A with global first-in-class potential and MRG007 with global best-in-class potential, all of which have shown encouraging pre-clinical data and received IND approvals in China. Pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.On August 1, 2025, the Company entered into a licensing transaction for the license-out and/or transfer of certain intellectual property rights relating to two preclinical assets developed by the Company’s proprietary T cell engager-TOPAbody platform with Excalipoint through entering into the Intellectual Property Assignment and License Agreement.The Company shall receive (i) an upfront payment in cash of US$10 million in aggregate, development and commercial milestone payments in cash of up to US$847.5 million in aggregate and sales royalties, holding a 10% interest, marking international recognition of the platform's value.Future Outlook: Accelerating the Commercialization of Core Products and Advancing Global Strategic DevelopmentIn respect of drug R&D, the Company will further focus on advancing strategic research and development priorities in next generation ADC drugs and IO bi/tri specific antibodies, while accelerating the commercialization of late-stage products. For our registrational stage product MRG003, the relevant authority is currently proceeding with the clinical and pharmaceutical evaluation in an orderly manner. The Company will concentrate our resources and endeavour to expedite the approval process. Meanwhile, our other key drug candidates are entering pivotal clinical stages. Protocol communication for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, we are currently conducting protocol communication with the CDE regarding the domestic pivotal clinical trial of CG0070. The Company will also explore further potential clinical value of our other innovative drug candidates, such as MRG006A and MRG007. Concurrently, the potential efficacy of combination therapies within our pipeline is being continuously explored, with greater clinical benefits striving to be delivered to a broader patient population.In terms of domestic commercialization, the Company will take further actions to enhance the market accessibility of PUYOUHENG (Pucotenlimab Injection), accelerating market penetration at all levels to further increase market share and enhance the Company's brand image and market recognition. At the same time, the Company will commence the preparation process for the commercial launch of MRG003 and continue to expand our marketing and commercialization teams.On the international front, the Company will ramp up our efforts to expand into the global market. We will expand our international network and explore new business development cooperation opportunities. The Company will remain committed to seeking more strategic partners worldwide to develop our ADC products and other innovative candidates through partnerships, licensing agreements, or joint ventures. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 22, 2025 - (ACN Newswire via SeaPRwire.com) - China International Development Corporation Limited (“the Company”; SEHK: 0264) is pleased to announce that it has entered into a definitive agreement to acquire a 20% equity interest in NVTHK Ltd. (“NVT”), a Hong Kong-based financial technology innovator and first mover in the Real-World Asset (“RWA”) tokenization market. This strategic acquisition positions the Company at the forefront of a sector expected to reshape global capital markets and deliver exponential growth in the years ahead.NVT — First Mover in a Transformative MarketNVT is the pioneering RWA tokenization infrastructure provider in Hong Kong, uniquely enabling primary issuance from top-tier financial institutions and on chain secondary trading of regulated tokenized assets through its robust OTC market place — the first full-scale ecosystem of its kind in the market.Its fully integrated, closed-loop ecosystem connects asset issuers, investors, and liquidity providers, unlocking unprecedented efficiency and liquidity for the financial industry.NVT’s prestigious institutional-grade clientele spans top financial institutions, asset managers, and Web3 innovators, including Cinda Asset Management, GF Securities, Golden Continent Asset Management, Animoca Brands, and HashKey Group. Its platform currently supports tokenized issuances across multiple financial product categories — including money market funds, structured products, bonds, private equity funds—demonstrating broad applicability and market acceptance.This Acquisition is Breakthrough for China International DevelopmentAccording to a BCG report dated April 2025, the global RWA tokenization market is forecast to grow from US$0.6 trillion in 2025 to US$18.9 trillion by 2033 in the midpoint scenario — a 53% compound annual growth rate. The sector’s rapid expansion reflects rising institutional and retail demand for high yield, transparent, and directly accessible asset classes.By acquiring a 20% stake in NVT, the Company gains:- A turnkey, proprietary institutional-grade tokenization platform — success-proven and fully regulated;- Access to the first RWA ecosystem in Hong Kong with secondary trading via an on chain OTC marketplace;- An established global distribution network with instant connectivity to liquidity providers, asset issuers, and investors globally;- Credibility and market access through alignment with a trusted RWA ecosystem serving blue chip clients.This acquisition accelerates the Company’s entry into the high growth RWA market at scale, without the delays, risks, and capital expenditure associated with building a platform from scratch. The Acquisition is also consistent with the Company’s commitments to exploring innovations and new business opportunities to diversify income streams.Strategic Collaboration AreasFollowing the investment, the Company and NVT will collaborate in two strategic areas:RWA Tokenization in Leather Production & Supply ChainLeveraging NVT’s platform, the Company will be a global first mover in tokenizing tangible and intangible assets within the leather industry—such as cash flows, receivables, inventory, and IP. This will unlock working capital, open new investment channels, automate settlements, and expand liquidity access worldwide.Expansion into New RWA VerticalsTogether, the Company and NVT will develop and scale RWA tokenization solutions for other industries, deploying the Company’s sector expertise and NVT’s proven infrastructure to capture untapped opportunities in multiple asset classes.Zhao Jingfei, CEO of China International Development Corporation Limited said:“This investment in NVT represents a breakthrough for our Company. NVT’s unmatched first mover position, its proven track record with prestigious institutional clients, and its unique on chain secondary trading capabilities place it in a category of its own. We are now positioned to participate meaningfully in a trillion dollar growth opportunity while modernizing our core business and delivering long term shareholder value.”Jay Zhao, the founder and CEO of NVT added:“Our mission is to leverage blockchain technology to redefine capital markets, with a particular focus on Hong Kong — the financial hub of Asia. By partnering with China Development, we are opening access to high quality assets from real-world industries and seamlessly integrating them into the capital market. This partnership not only enhances the strength of our platform but also creates significant opportunities for value creation across our ecosystem of partners, with a clear focus on maximizing long term shareholder returns. What we are building is just the beginning — the potential for new business models, innovative asset classes, and scalable growth ahead is truly limitless.”About NVTNVTHK Limited. (“NVT”) is a Hong Kong based fintech innovator specializing in real world asset (RWA) tokenization infrastructure, virtual asset brokerage systems, and stablecoin technology solutions. NVT is the first in Hong Kong to enable regulated tokenized assets to be traded on chain through its OTC marketplace, offering enterprise grade technology for issuers, investors, and intermediaries.About China International Development Corporation LimitedChina International Development Corporation Limited (“CIDC”) was incorporated in the Cayman Islands and is listed on the Main Board of The Stock Exchange of Hong Kong under stock code 0264. As an established investment holding company, CIDC has built a strong foundation in the manufacturing and distribution of high-quality leather products.  CIDC has proactively embarked on a strategy of innovation and transformation, seeking opportunities beyond its traditional core business. The Company is always committed to seeking opportunities for new business and value creation, as well as for timely expansion of the Company’s scope of operation and investments.For press enquiries:NVTHK LimitedOlivia Leung   Tel: 2522 3869 Email: Olivia.leung@newvisiongp.comWebsite: www.nvt.cim.hk Copyright 2025 ACN Newswire via SeaPRwire.com.